These data are harder to interpret due to the inherent variability in aneurysm size, location, degree of hemorrhage, etc.; nonetheless, they demonstrate that adropin can remain effective in a disease model that recapitulates the most common cause of non-traumatic SAH in human patients. This evidence concerns the gene ENHO and aneurysm.